Website update in progress

Following the transformation of Polpharma Biologics (learn more), this site will focus on biosimilars development in Switzerland. In Poland, we operate now as Rezon Bio – a contract developer and manufacturer of biologics (CDMO). More at www.rezonbio.com.

Due to the demerger of Polpharma Biologics into two independent companies (detailed information can be found in the “Knowledge center” section), the website polpharmabiologics.com is currently being updated. For details on the CDMO business, please visit the Rezon Bio website

Go to Rezon Bio website

Launching of the 4th edition of the Career Laboratory!

Published: 13.05.2019

We are starting recruitment for the 4th edition of our Career Laboratory internship program.

This program offers ambitious students and recent graduates the opportunity to develop skills by working alongside some of the industry’s leading professionals in one of the most modern biotechnology centers in Europe. It is available for graduates and students who are fluent in English and in the final years of their studies in biotechnology, biology, chemistry or a related science.

To read more info, check the website: http://www.laboratorium-kariery.pl/

Applications can be sent until 27 May

Career Laboratory

written by: Polpharma Biologics

Related news

Other news related to this topic that may be of interest to you

bioeq_ag

Press release

Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA

Published: 23.12.2025

December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG,...

nowybannerpb_Brazylia

Press release

Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases

Published: 10.12.2025

December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...

PolpharmaBiologics-confirms-US-launch-Tyruko

Press release

Polpharma Biologics confirms U.S. launch of Tyruko® (natalizumab), the first and only biosimilar for Multiple Sclerosis

Published: 17.11.2025

November 17, 2025 – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development...

banner_PB

Press release

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

Published: 21.10.2025

Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...